Registry to Detect and Prevent Heart Problems Caused by Cancer Treatments in Adults with Cancer

What this Trial Is About

Researchers are studying cancer-related cardiovascular toxicity, which includes heart problems caused by chemotherapy drugs and radiotherapy in people with cancer. The goal is to identify ways to predict, prevent, and treat heart damage related to cancer treatments. This observational study aims to better understand these cardiovascular risks in cancer patients to improve care. Participants include those newly diagnosed with breast cancer receiving anthracycline-based chemotherapy with or without radiotherapy, trastuzumab, or other anticancer drugs. A subgroup will have their risk assessed using the HFA-ICOS risk score. The study involves following patients at baseline, 3 months, and 1 year to monitor heart health and treatment effects. During the study, participants will attend follow-up visits for assessments, including heart function and survival outcomes. Researchers will track all-cause mortality, cardiovascular mortality, and cancer therapy-related cardiovascular toxicity over about three years. The study collects data to help better understand and manage heart risks linked to cancer treatments.

Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry